<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753740</url>
  </required_header>
  <id_info>
    <org_study_id>OVAR0801</org_study_id>
    <nct_id>NCT00753740</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.</brief_title>
  <official_title>A Phase II Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of Maintenance IT-101 in Platinum Sensitive Ovarian Cancer Patients Who Received 4-6 Cycles of a 2nd Line Platinum-Based Regimen Without Disease Progression.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NewLink Genetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NewLink Genetics Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the effect of IT-101 on delaying cancer progression in patients with
      platinum sensitive ovarian cancer.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Poor trial recruitment
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Compare the proportion of patients without evidence of disease progression at 30 weeks following randomization between IT-101 at 12 mg/m2/dose or 15 mg/m2/dose to a placebo infusion treatment administered every other week.</measure>
    <time_frame>30 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of adverse drug experiences between each treatment</measure>
    <time_frame>30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the frequency of drug-related toxicities between each treatment arm</measure>
    <time_frame>30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Quality of Life (QOL, patient-reported) measures (FACT-O, FOSI) between treatment arms.</measure>
    <time_frame>30 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>12mg/m2/dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12mg per meter squared per dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15mg/m2/dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg per meter squared per dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5% dextrose infusion (placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IT-101 (12mg/m2/dose)</intervention_name>
    <description>Patients who satisfy the inclusion/exclusion criteria will receive a blinded infusion of IT-101 (12mg/m2/dose) every other week until disease progression.</description>
    <arm_group_label>12mg/m2/dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IT-101 (15mg/m2/dose)</intervention_name>
    <description>Patients who satisfy the inclusion/exclusion criteria will receive an infusion of IT-101 (15mg/m2) every other week until disease progression.</description>
    <arm_group_label>15mg/m2/dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% Dextrose (Placebo)</intervention_name>
    <description>Patients who satisfy the inclusion/exclusion criteria will receive an infusion of placebo every other week until disease progression.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Women between the age of 18 and 78, inclusive;

          -  Evidence of platinum-sensitive ovarian cancer following the patient's primary
             treatment(&gt;= 6 months);

          -  Received a 2nd line platinum-based chemotherapy regimen (4-6 cycles) without evidence
             of progression;

          -  May have measurable or unmeasurable disease;

          -  Eastern Cooperative Oncology Group (ECOG) 0 or 1;

          -  Ability to understand and the willingness to sign a written informed consent document.

        Key Exclusion Criteria:

          -  Women who are pregnant or lactating;

          -  Prior treatment with a topoisomerase inhibitor;

          -  Patients with unacceptable organ and/or hematologic reserve at screening;

          -  Urine protein of &gt; 500 mg/day or active nephropathy;

          -  Electrocardiogram (ECG) with evidence of clinically significant conduction
             abnormalities or active ischemia as determined by the investigator;

          -  History of pancreatitis within the last 12 months;

          -  Patients treated with previous high dose chemotherapy or stem cell transplant within
             the last 5 years;

          -  Use of any investigational agents within 4 weeks of study enrollment;

          -  Uncontrolled intercurrent illness, including but not limited to, ongoing or active
             infection, psychiatric illness or other co-morbidity that presents a risk to the
             patient as determined by the investigator.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan S Berek, MD, MMS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor and Chair, Department of Obstetrics and Gynecology Stanford University School of Medicine Stanford Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franco Muggia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anne Murnick Cogan and David H. Cogan Professor of Oncology, Director of the Division of Medical Oncology at NYU Medical Center, and Associate Director for Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Decatur Memorial Hospital, Clinical Research Department/ Cancer Care Specialists of Illinois</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwartz Gynecologic Onclology, PLLC</name>
      <address>
        <city>Brightwaters</city>
        <state>New York</state>
        <zip>11718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga GYN Oncology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>97403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Gynecology &amp; Oncology</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.calandopharma.com/</url>
    <description>Calando Pharmaceuticals Website</description>
  </link>
  <reference>
    <citation>Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, Davis ME. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res. 2006 Mar 1;12(5):1606-14.</citation>
    <PMID>16533788</PMID>
  </reference>
  <reference>
    <citation>Schluep T, Cheng J, Khin KT, Davis ME. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol. 2006 May;57(5):654-62. Epub 2005 Aug 26.</citation>
    <PMID>16133526</PMID>
  </reference>
  <reference>
    <citation>Cheng J, Khin KT, Davis ME. Antitumor activity of beta-cyclodextrin polymer-camptothecin conjugates. Mol Pharm. 2004 May-Jun;1(3):183-93.</citation>
    <PMID>15981921</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2008</study_first_submitted>
  <study_first_submitted_qc>September 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <disposition_first_submitted>February 24, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>February 27, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 29, 2012</disposition_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Solid Malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

